|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FAM91A1 |
Gene summary for FAM91A1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FAM91A1 | Gene ID | 157769 |
| Gene name | family with sequence similarity 91 member A1 | |
| Gene Alias | FAM91A1 | |
| Cytomap | 8q24.13 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | Q658Y4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 157769 | FAM91A1 | P130T-E | Human | Esophagus | ESCC | 7.38e-39 | 7.82e-01 | 0.1676 |
| 157769 | FAM91A1 | HCC1_Meng | Human | Liver | HCC | 9.76e-63 | 1.48e-01 | 0.0246 |
| 157769 | FAM91A1 | HCC2_Meng | Human | Liver | HCC | 3.12e-27 | 1.97e-01 | 0.0107 |
| 157769 | FAM91A1 | HCC1 | Human | Liver | HCC | 2.29e-02 | 2.71e+00 | 0.5336 |
| 157769 | FAM91A1 | HCC2 | Human | Liver | HCC | 3.40e-31 | 4.04e+00 | 0.5341 |
| 157769 | FAM91A1 | Pt13.b | Human | Liver | HCC | 2.63e-09 | 1.96e-01 | 0.0251 |
| 157769 | FAM91A1 | Pt14.a | Human | Liver | HCC | 2.00e-05 | 3.99e-01 | 0.0169 |
| 157769 | FAM91A1 | S014 | Human | Liver | HCC | 1.19e-21 | 8.07e-01 | 0.2254 |
| 157769 | FAM91A1 | S015 | Human | Liver | HCC | 2.50e-20 | 1.01e+00 | 0.2375 |
| 157769 | FAM91A1 | S016 | Human | Liver | HCC | 4.92e-22 | 7.36e-01 | 0.2243 |
| 157769 | FAM91A1 | S027 | Human | Liver | HCC | 5.39e-13 | 1.26e+00 | 0.2446 |
| 157769 | FAM91A1 | S028 | Human | Liver | HCC | 1.10e-30 | 1.43e+00 | 0.2503 |
| 157769 | FAM91A1 | S029 | Human | Liver | HCC | 1.96e-29 | 1.48e+00 | 0.2581 |
| 157769 | FAM91A1 | C04 | Human | Oral cavity | OSCC | 1.06e-20 | 8.69e-01 | 0.2633 |
| 157769 | FAM91A1 | C21 | Human | Oral cavity | OSCC | 2.18e-28 | 7.52e-01 | 0.2678 |
| 157769 | FAM91A1 | C30 | Human | Oral cavity | OSCC | 1.70e-45 | 1.43e+00 | 0.3055 |
| 157769 | FAM91A1 | C38 | Human | Oral cavity | OSCC | 4.12e-08 | 6.33e-01 | 0.172 |
| 157769 | FAM91A1 | C43 | Human | Oral cavity | OSCC | 3.09e-09 | 2.39e-01 | 0.1704 |
| 157769 | FAM91A1 | C51 | Human | Oral cavity | OSCC | 1.54e-25 | 1.00e+00 | 0.2674 |
| 157769 | FAM91A1 | C57 | Human | Oral cavity | OSCC | 2.15e-17 | 5.05e-01 | 0.1679 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:005165016 | Esophagus | ESCC | establishment of vesicle localization | 114/8552 | 161/18723 | 8.20e-11 | 2.53e-09 | 114 |
| GO:005164815 | Esophagus | ESCC | vesicle localization | 119/8552 | 177/18723 | 5.16e-09 | 1.08e-07 | 119 |
| GO:00069038 | Esophagus | ESCC | vesicle targeting | 38/8552 | 45/18723 | 8.42e-08 | 1.43e-06 | 38 |
| GO:00990222 | Esophagus | ESCC | vesicle tethering | 10/8552 | 11/18723 | 2.54e-03 | 1.08e-02 | 10 |
| GO:005165621 | Liver | HCC | establishment of organelle localization | 226/7958 | 390/18723 | 4.15e-10 | 1.34e-08 | 226 |
| GO:005165021 | Liver | HCC | establishment of vesicle localization | 103/7958 | 161/18723 | 2.94e-08 | 6.69e-07 | 103 |
| GO:005164821 | Liver | HCC | vesicle localization | 107/7958 | 177/18723 | 1.05e-06 | 1.57e-05 | 107 |
| GO:000690311 | Liver | HCC | vesicle targeting | 34/7958 | 45/18723 | 6.75e-06 | 8.08e-05 | 34 |
| GO:005165610 | Oral cavity | OSCC | establishment of organelle localization | 239/7305 | 390/18723 | 2.46e-19 | 3.31e-17 | 239 |
| GO:00069037 | Oral cavity | OSCC | vesicle targeting | 38/7305 | 45/18723 | 4.49e-10 | 1.19e-08 | 38 |
| GO:00516509 | Oral cavity | OSCC | establishment of vesicle localization | 101/7305 | 161/18723 | 8.79e-10 | 2.17e-08 | 101 |
| GO:00516489 | Oral cavity | OSCC | vesicle localization | 105/7305 | 177/18723 | 3.30e-08 | 6.30e-07 | 105 |
| GO:0099022 | Oral cavity | OSCC | vesicle tethering | 10/7305 | 11/18723 | 5.78e-04 | 3.30e-03 | 10 |
| GO:005165615 | Oral cavity | LP | establishment of organelle localization | 147/4623 | 390/18723 | 6.01e-09 | 2.46e-07 | 147 |
| GO:000690314 | Oral cavity | LP | vesicle targeting | 27/4623 | 45/18723 | 5.03e-07 | 1.40e-05 | 27 |
| GO:005165015 | Oral cavity | LP | establishment of vesicle localization | 64/4623 | 161/18723 | 1.65e-05 | 2.86e-04 | 64 |
| GO:005164814 | Oral cavity | LP | vesicle localization | 66/4623 | 177/18723 | 1.25e-04 | 1.46e-03 | 66 |
| GO:005165623 | Oral cavity | EOLP | establishment of organelle localization | 73/2218 | 390/18723 | 4.59e-05 | 6.11e-04 | 73 |
| GO:005165022 | Oral cavity | EOLP | establishment of vesicle localization | 35/2218 | 161/18723 | 2.54e-04 | 2.47e-03 | 35 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FAM91A1 | SNV | Missense_Mutation | rs201587994 | c.1253N>C | p.Asp418Ala | p.D418A | Q658Y4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A2-A0CQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
| FAM91A1 | SNV | Missense_Mutation | c.1681N>T | p.Pro561Ser | p.P561S | Q658Y4 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
| FAM91A1 | SNV | Missense_Mutation | rs201587994 | c.1253A>C | p.Asp418Ala | p.D418A | Q658Y4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FAM91A1 | SNV | Missense_Mutation | c.1000N>T | p.Asp334Tyr | p.D334Y | Q658Y4 | protein_coding | deleterious(0.01) | possibly_damaging(0.563) | TCGA-A8-A08P-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | CR | |
| FAM91A1 | SNV | Missense_Mutation | c.1261C>G | p.Leu421Val | p.L421V | Q658Y4 | protein_coding | tolerated(0.08) | probably_damaging(0.986) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM91A1 | SNV | Missense_Mutation | rs201587994 | c.1253N>C | p.Asp418Ala | p.D418A | Q658Y4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
| FAM91A1 | SNV | Missense_Mutation | c.1261N>G | p.Leu421Val | p.L421V | Q658Y4 | protein_coding | tolerated(0.08) | probably_damaging(0.986) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| FAM91A1 | SNV | Missense_Mutation | c.215N>A | p.Arg72Gln | p.R72Q | Q658Y4 | protein_coding | tolerated(0.08) | probably_damaging(0.986) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM91A1 | SNV | Missense_Mutation | c.1522A>G | p.Thr508Ala | p.T508A | Q658Y4 | protein_coding | tolerated(0.07) | benign(0.037) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| FAM91A1 | SNV | Missense_Mutation | rs201587994 | c.1253N>C | p.Asp418Ala | p.D418A | Q658Y4 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AO-A0J5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Other, specify in notesBisphosphonate | zoledronic | PD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |